welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Marina Biotech Announces $1.1 MM Convertible Preferred Stock Financing
Marina Biotech, Inc. ( OTCQB : MRNA ), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the company has entered into a definitive agreement with existing investors, led by Steven T. Newby and James H. Stebbins, for the issuance of convertible preferred stock at a conversion price equivalent to $0.40 per share of common stock resulting in gross proceeds to the company of $1.1 million. In addition, the Company will issue to the investors warrants to purchase up to 3,437,500 shares of common stock. The warrants will have an exercise price of $0.40 per share and are exercisable for a period of six years after the date of issuance. The offering is expected to close on or about August 7, 2015, subject to the satisfaction of customary closing conditions.
expertly curated content related to this topic
-
OHSU Knight Cancer InstituteDriven by its mission to end cancer, OHS...
-
Janette Lawrence, CGCBoard certified and licensed Genetic Cou...
-
HELIOS Klinikum WuppertalCenter for Hereditary Tumor Di...
-
University of California, San Francisco Medical CenterPatient Resources: Center...
-
Cancer Insurance ChecklistThe Cancer Insurance Checklist is design...
-
Karen A. Brooks, MS, CGCGenetic Counselor Specializations: Fa...
-
Daniel ShockleyDaniel Shockley at the age of 51, receiv...